Gå direkt till huvudinnehållet

Narkolepsi

Senast uppdaterad: Senast reviderad:
Sakkunnig:
Definition:
Kronisk neurologisk störning av sömn- vakenhetsregleringen med uttalad sömnighet under dagen.
Förekomst:
Prevalens anges ofta till 0,05 %, det vill säga cirka 4 500 till 5 000 patienter i Sverige.
Symtom:
Generellt uttalad sömnighet på dagtid med anfall med abnormt sömnbehov. Typiskt är också kataplexi, hypnagogiska hallucinationer och sömnparalys.
Kliniska fynd:
Fysisk undersökning är normal.
Diagnos:
Typisk anamnes. Tillståndet verifieras med undersökning i ett sömnlaboratorium/neurofysologiskt laboratorium.
Behandling:
Behandlingen består av information och anpassningar på jobbet eller i skolan. Läkemedelsbehandling ges mot sömnighet, kataplexi och hypnagogiska hallucinationer.
  1. Scammell TE. Narcolepsy. N Engl J Med. 2015; Dec 31;373(27): 2654-62. pmid:26716917 PubMed  
  2. Zeman A, Britton T, Douglas N, Hansen A, Hicks J, Howard R, Meredith A, Smith I, Stores G, Wilson S, Zaiwalla Z. Narcolepsy and excessive daytime sleepiness. BMJ. 2004 Sep 25;329(7468):724-8. doi: 10.1136/bmj.329.7468.724. PMID: 15388615 PubMed  
  3. Bassetti CLA, Adamantidis A, Burdakov D, Han F, Gay S, Kallweit U, Khatami R, Koning F, Kornum BR, Lammers GJ, Liblau RS, Luppi PH, Mayer G, Pollmächer T, Sakurai T, Sallusto F, Scammell TE, Tafti M, Dauvilliers Y. Narcolepsy - clinical spectrum, aetiopathophysiology, diagnosis and treatment. Nat Rev Neurol. 2019 Sep;15(9):519-539. doi: 10.1038/s41582-019-0226-9. Epub 2019 Jul 19. PMID: 31324898 PubMed  
  4. Britton T, Douglas N, Hansen A, Hicks J, Howard R, Meredith A, et al. Guidelines on the diagnosis and management of narcolepsy in adults and children. Ashtead: Taylor Patten Communications, 2002 (available at www.sleeping.org.uk or www.primarycaresleep.com).
  5. Overeem S, Mignot E, van Dijk JG, Lammers GJ. Narcolepsy: clinical features, new pathophysiologic insights and future perspectives. J Clin Neurophysiol 2001; 18: 78-105. PubMed  
  6. Billiard M. Diagnosis of narcolepsy and idiopathic hypersomnia: an update based on the international classification of sleep disorders, 2nd edition. Sleep Med Rev 2007; 11(5): 377–88. www.ncbi.nlm.nih.gov  
  7. Judd BG, Sateia MJ. Classification of sleep disorders. UpToDate 2017 - last updated may 2015. www.uptodate.com  
  8. Silber MH, Krahn LE, Pankratz VS. The epidemiology of narcolepsy in Olmstead County, Minnesota: a population-based study. . Sleep 2002; 25: 197-202. pmid:11902429 PubMed  
  9. Longstreth WT Jr, Koepsell TD, Ton TG. The epidemiology of narcolepsy. Sleep 2007; 30: 13. pmid:17310860 PubMed  
  10. Sand T, Schrader H. Narkolepsi og andre hypersomnier. Oversiktsartikkel. Tidsskr Nor Legeforen 2009; 129: 2007-10. Tidsskrift for Den norske legeforening  
  11. Mignot E. Genetic and familial aspects of narcolepsy. Neurology 1998; 50(suppl 1): 516-22.
  12. Narkolepsi. Sällsynta hälsotillstånd. Socialstyrelsen. hämtad 210726 www.socialstyrelsen.se  
  13. National institute for health and welfare. Association between Pandemrix and narcolepsy confirmed among Finnish children and adolescents. Sept. 1, 2011.
  14. Sarkanen T, Alakuijala A, Partinen M. Clinical course of H1N1-vaccine-related narcolepsy. Sleep Med 2016; 19: 17-22. pmid:27198942 PubMed  
  15. Hobson JA, Pace-Schott EF. The cognitive neuroscience of sleep. Nat Rev Neurosci 2002; 3: 670-93. PubMed  
  16. Pace-Schott EF, Hobson JA. The neurobiology of sleep. Nat Rev Neurosci 2002; 3: 591-605. PubMed  
  17. Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy letter. Lancet 2000; 355: 39-40. PubMed  
  18. Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y, et al. A mutation in a case of early onset narcolepsy and a generalised absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000; 6: 991-7. PubMed  
  19. Thannickal TC, Moore RY, Nienhuls R, Ramanathan L, Gulyani S, Aldrich M, et al. Reduced numbers of hypocretin neurons in human narcolepsy. Neuron 2000; 27: 469-74. PubMed  
  20. Mignot E, Lammers GJ, Ripley B, Okun M, Nevsimalova S, Overeem S, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002; 59: 1553-62. PubMed  
  21. Scammell T. The neurobiology, diagnosis and treatment of narcolepsy. Ann Neurol 2003; 53: 154-66. PubMed  
  22. Tafti M, Hor H, Dauvilliers Y, et al. DQB1 locus alone explains most of the risk and protection in narcolepsy with cataplexy in Europe. Sleep 2014; 37: 19-25. pmid:24381371 PubMed  
  23. Miyagawa T, Tokunaga K. Genetics of narcolepsy. Hum Genome Var 2019; 8: eCollection 2019. pmid:30652006 PubMed  
  24. Mignot E, Hayduk R, Black J, Grumet FC, Guilleminault C. HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. Sleep 1997; 20: 1012-20. PubMed  
  25. Kim J, Lee GH, Sung SM, Jung DS, Pak K. Prevalence of attention deficit hyperactivity disorder symptoms in narcolepsy: a systematic review. Sleep Med. 2020 Jan;65:84-88. doi: 10.1016/j.sleep.2019.07.022. Epub 2019 Aug 3. PMID: 31739230. PubMed  
  26. Ruge Møller L, Østergaard JR. Narkolepsi hos børn - en overset diagnose. Ugeskr Læger 2005; 167: 2390-3. PubMed  
  27. Guilleminault C, Pelayo R. Nacolepsy in children. Paediatr Drugs 2000; 2-9.
  28. Merrill S, Wise MD. Childhood narcolepsy. Neurology 1998; 50(suppl 1): S37-S42.
  29. Guilleminault C. Narcolepsy in prepubertal children. Ann Neurol 1998; 43: 135-42. PubMed  
  30. McKenna L, McNicholas F. Childhood onset narcolepsy. Eur Child Adolesc Psychiatry 2003; 12: 43-7. PubMed  
  31. Babiker MO, Prasad M. Narcolepsy in children: a diagnostic and management approach. Pediatr Neurol 2015; 52: 557-65. pmid:25838042 PubMed  
  32. Stores G. Recognition and management of narcolepsy. Arch Dis Child 1998; 81: 519-24. PubMed  
  33. Daniels E, King MA, Smith IE, Shneerson JM. Health-related quality of life in narcolepsy. J Sleep Res 2001; 10: 75-81. PubMed  
  34. Johns MJ. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991; 6: 540-5. PubMed  
  35. Standard of Practice Committee, American Academy of Sleep Medicine. Practice parameters for the treatment of narcolepsy. Sleep 2001; 24: 451-66. PubMed  
  36. Dauvilliers Y, Lecendreux M, Lammers GJ, et al. Safety and efficacy of pitolisant in children aged 6 years or older with narcolepsy with or without cataplexy: a double-blind, randomised, placebo-controlled trial. Lancet Neurol 2023; 22: 303-311. pmid:36931805 PubMed  
  37. Rogers AE, Aldrich MS, Lin X. A comparison of three different sleep schedules for reducing daytime sleepiness in narcolepsy. Sleep 2001; 24: 385-91. PubMed  
  38. Riktlinje för behandling av narkolepsi hos barn och vuxna. NPO Nervsystemets sjukdomar. Nationellt system för kunskapsstyrning Hälso- och sjukvård. Sveriges regioner i samverkan (hämtad 2022-04-11) nationelltklinisktkunskapsstod.se  
  39. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. Neurology 2000; 54: 1166-75. Neurology  
  40. Scammell TE, Benca R. Treatment of narcolepsy. UpToDate 2013 UpToDate  
  41. Vignatelli L, D'Alessandro R, Candelise L. Antidepressant drugs for narcolepsy. Cochrane Database of Systematic Reviews 2008, Issue 1. Art. No.: CD003724. DOI: 10.1002/14651858.CD003724.pub3. DOI  
  42. Alshaikh MK, Tricco AC, Tashkandi M, et al. Sodium oxybate for narcolepsy with cataplexy: systematic review and meta-analysis. J Clin Sleep Med 2012; 8: 451-8. pmid:22893778 PubMed  
  43. Transportstyrelsens författningssamling 2013:2 www.transportstyrelsen.se  
  • Anna Nager, docent och specialist i allmänmedicin, Karolinska institutet

Tidigare sakkunniga

  • Bjørn Bjorvatn, professor dr.med., Institutt for global helse og samfunnsmedisin, Universitetet i Bergen, og leder av Nasjonal kompetansetjeneste for søvnsykdommer, Haukeland Universitetssykehus
  • Ingard Løge, spesialist allmennmedisin, redaktør NEL